All In Biotech

Drug Trial Radar · NCT06161571

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Nov 10, 2023

Primary completion

Mar 3, 2026

Study completion Jun 19, 2026

Sponsor

Lead sponsor
Akero Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Dec 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD.

Conditions

  • NASH/MASH
  • NAFLD/MASLD

Interventions

  • EfruxiferminDrug

    Administered by subcutaneous (SC) injection

  • PlaceboDrug

    Administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Extent of exposureTime frame: 52 Weeks
  2. Number of participants with adverse eventsTime frame: 52 Weeks
  3. Number of participants with adverse events by severityTime frame: 52 Weeks
  4. Number of participants with clinically significant changes in clinical assessmentsTime frame: 52 Weeks

Locations

211 sites in 13 countries. Site status is shown where the registry gives one.

  • Akero Clinical Study Site

    Birmingham, Alabama

  • Akero Clinical Study Site

    Chandler, Arizona

  • Akero Clinical Study Site

    Flagstaff, Arizona

  • Akero Clinical Study Site

    Peoria, Arizona

  • Akero Clinical Study Site

    Tucson, Arizona

  • Akero Clinical Study Site

    Tucson, Arizona

  • Akero Clinical Study Site

    Conway, Arkansas

  • Akero Clinical Study Site

    Jonesboro, Arkansas

  • Akero Clinical Study Site

    Little Rock, Arkansas

  • Akero Clinical Study Site

    North Little Rock, Arkansas

  • Akero Clinical Study Site

    Chula Vista, California

  • Akero Clinical Study Site

    Coronado, California

  • Akero Clinical Study Site

    Cypress, California

  • Akero Clinical Study Site

    Inglewood, California

  • Akero Clinical Study Site

    La Mesa, California

  • Akero Clinical Study Site

    Lancaster, California

  • Akero Clinical Study Site

    Los Angeles, California

  • Akero Clinical Study Site

    Los Angeles, California

  • Akero Clinical Study Site

    Palm Springs, California

  • Akero Clinical Study Site

    San Diego, California

  • Akero Clinical Study Site

    San Diego, California

  • Akero Clinical Study Site

    San Francisco, California

  • Akero Clinical Study Site

    Santa Maria, California

  • Akero Clinical Study Site

    Englewood, Colorado

  • Akero Clinical Study Site

    Bradenton, Florida

  • Akero Clinical Study Site

    Brandon, Florida

  • Akero Clinical Study Site

    Fort Myers, Florida

  • Akero Clinical Study Site

    Gainesville, Florida

  • Akero Clinical Study Site

    Hialeah Gardens, Florida

  • Akero Clinical Study Site

    Inverness, Florida

  • Akero Clinical Study Site

    Jacksonville, Florida

  • Akero Clinical Study Site

    Lady Lake, Florida

  • Akero Clinical Study Site

    Lakewood Rch, Florida

  • Akero Clinical Study Site

    Largo, Florida

  • Akero Clinical Study Site

    Maitland, Florida

  • Akero Clinical Study Site

    Miami, Florida

  • Akero Clinical Study Site

    Miami Lakes, Florida

  • Akero Clinical Study Site

    Naples, Florida

  • Akero Clinical Study Site

    Ocala, Florida

  • Akero Clinical Study Site

    Port Orange, Florida

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.